Experimental Therapeutics of Pediatric Hematopoietic Malignancies

主要目标是开发儿童白血病和淋巴瘤的新疗法。 以下项目目前正在进行或筹备中：1）抗CD 22免疫毒素， 儿童白血病和淋巴瘤的治疗2）非清髓性， HLA配型异基因干细胞移植治疗儿童白血病和淋巴瘤 未结合的单克隆抗体治疗儿童淋巴瘤4）EPOCH-利妥昔单抗 儿童期HIV相关非霍奇金淋巴瘤5）UCN-01在复发或复发性淋巴瘤中的II期研究 难治性系统性间变性大细胞和成熟T细胞淋巴瘤6）WT 1 用于血液肿瘤的肽转导的同种异体树突状细胞疫苗 血液生化学研究

The primary goal is to develop new treatments for childhood leukemias and lymphomas. The following projects are currently underway or in preparation: 1) Anti-CD22 Immunotoxins for Treatment of Leukemias and Lymphomas in Childhood 2) Pilot Study of Non-Myeloablative, HLA-Matched Allogeneic Stem Cell Transplantation in Pediatric Leukemias and Lymphomas 3) Unconjugated Monoclonal Antibodies for Treatment Lymphomas In Childhood 4) EPOCH-Rituximab for HIV-Associated Non-Hodgkin's Lymphomas In Childhood 5) Phase II Study of UCN-01 In Relapsed Or Refractory Systemic Anaplastic Large Cell And Mature T-Cell Lymphomas 6) WT1 Peptide-Transduced Allogeneic Dendritic Cell Vaccine for Hematologic Malignancies 7) Hematologic Malignancy Biology Study